tetano
Editor, Senior Moderator
Diabetol Metab Syndr
. 2021 Jan 12;13(1):5.
doi: 10.1186/s13098-020-00622-3.
Overall reduced lymphocyte especially T and B subsets closely related to the poor prognosis and the disease severity in severe patients with COVID-19 and diabetes mellitus
Dafeng Liu[SUP] 1 [/SUP], Yong Wang[SUP] 2 [/SUP], Bennan Zhao[SUP] 2 [/SUP], Lijuan Lan[SUP] 2 [/SUP], Yaling Liu[SUP] 2 [/SUP], Lei Bao[SUP] 2 [/SUP], Hong Chen[SUP] 3 [/SUP], Min Yang[SUP] 4 [/SUP], Qingfeng Li[SUP] 5 [/SUP], Yilan Zeng[SUP] 6 [/SUP]
Affiliations
Abstract
Background: A dysregulated host immune response is common in patients with COVID-19.
Aim: In this study, we aimed to define the characteristics of lymphocyte subsets and their relationship with disease progression in COVID-19 patients with or without diabetes mellitus (DM).
Methods: The baseline peripheral lymphocyte subsets were compared between 55 healthy controls and 95 patients with confirmed COVID-19, and between severe and non-severe COVID-19 patients with or without DM.
Results: The prevalence of DM in the COVID-19 group was 20%, and patients with severe COVID-19 had a higher prevalence of DM than those with non-severe disease (P = 0.006). Moreover, a significantly poor prognosis and a higher rate of severity were found in those with DM relative to those without DM (P = 0.001, 0.003). Generally, all lymphocytes and subsets of lymphocytes, especially B and T cells, were significant reduced in COVID-19 patients, particularly in those with DM. Patients with severe COVID-19 and DM had the lowest lymphocyte counts compared with those with severe COVID-19 without DM, and those with non-severe COVID-19 with or without DM. Partially decreased lymphocyte subsets, age and DM were closely related to disease progression and prognosis.
Conclusions: These findings provide a reference for clinicians that immunomodulatory treatment may improve disease progression and prognosis of COVID-19 patients, especially those with severe disease with DM. Trial registration Chinese Clinical Trial Register ChiCTR2000034563.
Keywords: Coronavirus disease 2019 (COVID-19); Diabetes mellitus; Disease severity; Lymphocyte subsets; Prognosis.
. 2021 Jan 12;13(1):5.
doi: 10.1186/s13098-020-00622-3.
Overall reduced lymphocyte especially T and B subsets closely related to the poor prognosis and the disease severity in severe patients with COVID-19 and diabetes mellitus
Dafeng Liu[SUP] 1 [/SUP], Yong Wang[SUP] 2 [/SUP], Bennan Zhao[SUP] 2 [/SUP], Lijuan Lan[SUP] 2 [/SUP], Yaling Liu[SUP] 2 [/SUP], Lei Bao[SUP] 2 [/SUP], Hong Chen[SUP] 3 [/SUP], Min Yang[SUP] 4 [/SUP], Qingfeng Li[SUP] 5 [/SUP], Yilan Zeng[SUP] 6 [/SUP]
Affiliations
- PMID: 33436069
- PMCID: PMC7802992
- DOI: 10.1186/s13098-020-00622-3
Abstract
Background: A dysregulated host immune response is common in patients with COVID-19.
Aim: In this study, we aimed to define the characteristics of lymphocyte subsets and their relationship with disease progression in COVID-19 patients with or without diabetes mellitus (DM).
Methods: The baseline peripheral lymphocyte subsets were compared between 55 healthy controls and 95 patients with confirmed COVID-19, and between severe and non-severe COVID-19 patients with or without DM.
Results: The prevalence of DM in the COVID-19 group was 20%, and patients with severe COVID-19 had a higher prevalence of DM than those with non-severe disease (P = 0.006). Moreover, a significantly poor prognosis and a higher rate of severity were found in those with DM relative to those without DM (P = 0.001, 0.003). Generally, all lymphocytes and subsets of lymphocytes, especially B and T cells, were significant reduced in COVID-19 patients, particularly in those with DM. Patients with severe COVID-19 and DM had the lowest lymphocyte counts compared with those with severe COVID-19 without DM, and those with non-severe COVID-19 with or without DM. Partially decreased lymphocyte subsets, age and DM were closely related to disease progression and prognosis.
Conclusions: These findings provide a reference for clinicians that immunomodulatory treatment may improve disease progression and prognosis of COVID-19 patients, especially those with severe disease with DM. Trial registration Chinese Clinical Trial Register ChiCTR2000034563.
Keywords: Coronavirus disease 2019 (COVID-19); Diabetes mellitus; Disease severity; Lymphocyte subsets; Prognosis.